Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades

Laura J. Esserman, Christina Yau, Carlie K. Thompson, Laura J. Van 't Veer, Alexander D Borowsky, Katherine A. Hoadley, Nicholas P. Tobin, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Christopher C. Benz, Linda S. Lindström

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

IMPORTANCE The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. OBJECTIVE To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. DESIGN, SETTING, AND PARTICIPANTS This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up. An indolent threshold (ultralow risk) of the US Food and Drug Administration–cleared MammaPrint 70-gene expression score was established above which no breast cancer deaths occurred after 15 years in the absence of systemic therapy. Immunohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 652 women), were performed from formalin-fixed paraffin-embedded primary tumor blocks. Participants were postmenopausal women with clinically detected node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamoxifen (STO-3) trial, 1976 to 1990. EXPOSURES After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status, patients without relapse who reconsented were further randomized to 3 additional years or none. MAIN OUTCOMES AND MEASURES Breast cancer–specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional hazard modeling, adjusted for treatment, patient age, year of diagnosis, tumor size, grade, hormone receptors, and ERBB2/HER2 and Ki67 status. RESULTS In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammography screening, among the 652 women with MammaPrint scoring available (median age, 62.8 years of age), 377 (58%) and 275 (42%) were MammaPrint low and high risk, respectively, while 98 (15%) were ultralow risk. At 20 years, women with 70-gene high and low tumors but not ultralow tumors had a significantly higher risk of disease-specific death compared with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95% CI, 1.38-16.22] and 4.54 [95% CI, 1.40-14.80], respectively). There were no deaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year disease-specific survival rate of 97%, whereas for untreated patients the survival rate was 94%. Recursive partitioning identified ultralow risk as the most significant predictor of good outcome. In tumors “not ultralow risk,” tumor size greater than 2 cm was the most predictive of outcome. CONCLUSIONS AND RELEVANCE The ultralow-risk threshold of the 70-gene MammaPrint assay can identify patients whose long-term systemic risk of death from breast cancer after surgery alone is exceedingly low.

Original languageEnglish (US)
Pages (from-to)1503-1510
Number of pages8
JournalJAMA oncology
Volume3
Issue number11
DOIs
StatePublished - Nov 1 2017

Fingerprint

Breast Neoplasms
Tamoxifen
Neoplasms
Survival Rate
Hormones
Segmental Mastectomy
Mastectomy
Kaplan-Meier Estimate
Mammography
Therapeutics
Paraffin
Formaldehyde
Genes
Breast
Arm
Randomized Controlled Trials
Radiation
Gene Expression
Recurrence
Food

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Esserman, L. J., Yau, C., Thompson, C. K., Van 't Veer, L. J., Borowsky, A. D., Hoadley, K. A., ... Lindström, L. S. (2017). Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. JAMA oncology, 3(11), 1503-1510. https://doi.org/10.1001/jamaoncol.2017.1261

Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. / Esserman, Laura J.; Yau, Christina; Thompson, Carlie K.; Van 't Veer, Laura J.; Borowsky, Alexander D; Hoadley, Katherine A.; Tobin, Nicholas P.; Nordenskjöld, Bo; Fornander, Tommy; Stål, Olle; Benz, Christopher C.; Lindström, Linda S.

In: JAMA oncology, Vol. 3, No. 11, 01.11.2017, p. 1503-1510.

Research output: Contribution to journalArticle

Esserman, LJ, Yau, C, Thompson, CK, Van 't Veer, LJ, Borowsky, AD, Hoadley, KA, Tobin, NP, Nordenskjöld, B, Fornander, T, Stål, O, Benz, CC & Lindström, LS 2017, 'Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades', JAMA oncology, vol. 3, no. 11, pp. 1503-1510. https://doi.org/10.1001/jamaoncol.2017.1261
Esserman, Laura J. ; Yau, Christina ; Thompson, Carlie K. ; Van 't Veer, Laura J. ; Borowsky, Alexander D ; Hoadley, Katherine A. ; Tobin, Nicholas P. ; Nordenskjöld, Bo ; Fornander, Tommy ; Stål, Olle ; Benz, Christopher C. ; Lindström, Linda S. / Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades. In: JAMA oncology. 2017 ; Vol. 3, No. 11. pp. 1503-1510.
@article{65b881337cf64e58a0a7d00c0240418b,
title = "Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades",
abstract = "IMPORTANCE The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. OBJECTIVE To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. DESIGN, SETTING, AND PARTICIPANTS This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up. An indolent threshold (ultralow risk) of the US Food and Drug Administration–cleared MammaPrint 70-gene expression score was established above which no breast cancer deaths occurred after 15 years in the absence of systemic therapy. Immunohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 652 women), were performed from formalin-fixed paraffin-embedded primary tumor blocks. Participants were postmenopausal women with clinically detected node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamoxifen (STO-3) trial, 1976 to 1990. EXPOSURES After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status, patients without relapse who reconsented were further randomized to 3 additional years or none. MAIN OUTCOMES AND MEASURES Breast cancer–specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional hazard modeling, adjusted for treatment, patient age, year of diagnosis, tumor size, grade, hormone receptors, and ERBB2/HER2 and Ki67 status. RESULTS In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammography screening, among the 652 women with MammaPrint scoring available (median age, 62.8 years of age), 377 (58{\%}) and 275 (42{\%}) were MammaPrint low and high risk, respectively, while 98 (15{\%}) were ultralow risk. At 20 years, women with 70-gene high and low tumors but not ultralow tumors had a significantly higher risk of disease-specific death compared with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95{\%} CI, 1.38-16.22] and 4.54 [95{\%} CI, 1.40-14.80], respectively). There were no deaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year disease-specific survival rate of 97{\%}, whereas for untreated patients the survival rate was 94{\%}. Recursive partitioning identified ultralow risk as the most significant predictor of good outcome. In tumors “not ultralow risk,” tumor size greater than 2 cm was the most predictive of outcome. CONCLUSIONS AND RELEVANCE The ultralow-risk threshold of the 70-gene MammaPrint assay can identify patients whose long-term systemic risk of death from breast cancer after surgery alone is exceedingly low.",
author = "Esserman, {Laura J.} and Christina Yau and Thompson, {Carlie K.} and {Van 't Veer}, {Laura J.} and Borowsky, {Alexander D} and Hoadley, {Katherine A.} and Tobin, {Nicholas P.} and Bo Nordenskj{\"o}ld and Tommy Fornander and Olle St{\aa}l and Benz, {Christopher C.} and Lindstr{\"o}m, {Linda S.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1001/jamaoncol.2017.1261",
language = "English (US)",
volume = "3",
pages = "1503--1510",
journal = "JAMA oncology",
issn = "2374-2437",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - Use of molecular tools to identify patients with indolent breast cancers with ultralow risk over 2 decades

AU - Esserman, Laura J.

AU - Yau, Christina

AU - Thompson, Carlie K.

AU - Van 't Veer, Laura J.

AU - Borowsky, Alexander D

AU - Hoadley, Katherine A.

AU - Tobin, Nicholas P.

AU - Nordenskjöld, Bo

AU - Fornander, Tommy

AU - Stål, Olle

AU - Benz, Christopher C.

AU - Lindström, Linda S.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - IMPORTANCE The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. OBJECTIVE To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. DESIGN, SETTING, AND PARTICIPANTS This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up. An indolent threshold (ultralow risk) of the US Food and Drug Administration–cleared MammaPrint 70-gene expression score was established above which no breast cancer deaths occurred after 15 years in the absence of systemic therapy. Immunohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 652 women), were performed from formalin-fixed paraffin-embedded primary tumor blocks. Participants were postmenopausal women with clinically detected node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamoxifen (STO-3) trial, 1976 to 1990. EXPOSURES After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status, patients without relapse who reconsented were further randomized to 3 additional years or none. MAIN OUTCOMES AND MEASURES Breast cancer–specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional hazard modeling, adjusted for treatment, patient age, year of diagnosis, tumor size, grade, hormone receptors, and ERBB2/HER2 and Ki67 status. RESULTS In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammography screening, among the 652 women with MammaPrint scoring available (median age, 62.8 years of age), 377 (58%) and 275 (42%) were MammaPrint low and high risk, respectively, while 98 (15%) were ultralow risk. At 20 years, women with 70-gene high and low tumors but not ultralow tumors had a significantly higher risk of disease-specific death compared with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95% CI, 1.38-16.22] and 4.54 [95% CI, 1.40-14.80], respectively). There were no deaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year disease-specific survival rate of 97%, whereas for untreated patients the survival rate was 94%. Recursive partitioning identified ultralow risk as the most significant predictor of good outcome. In tumors “not ultralow risk,” tumor size greater than 2 cm was the most predictive of outcome. CONCLUSIONS AND RELEVANCE The ultralow-risk threshold of the 70-gene MammaPrint assay can identify patients whose long-term systemic risk of death from breast cancer after surgery alone is exceedingly low.

AB - IMPORTANCE The frequency of cancers with indolent behavior has increased with screening. Better tools to identify indolent tumors are needed to avoid overtreatment. OBJECTIVE To determine if a multigene classifier is associated with indolent behavior of invasive breast cancers in women followed for 2 decades. DESIGN, SETTING, AND PARTICIPANTS This is a secondary analysis of a randomized clinical trial of tamoxifen vs no systemic therapy, with more than 20-year follow-up. An indolent threshold (ultralow risk) of the US Food and Drug Administration–cleared MammaPrint 70-gene expression score was established above which no breast cancer deaths occurred after 15 years in the absence of systemic therapy. Immunohistochemical markers (n = 727 women) and Agilent microarrays, for MammaPrint risk scoring (n = 652 women), were performed from formalin-fixed paraffin-embedded primary tumor blocks. Participants were postmenopausal women with clinically detected node-negative breast cancers treated with mastectomy or lumpectomy and radiation enrolled in the Stockholm tamoxifen (STO-3) trial, 1976 to 1990. EXPOSURES After 2 years of tamoxifen vs no systemic therapy, regardless of hormone receptor status, patients without relapse who reconsented were further randomized to 3 additional years or none. MAIN OUTCOMES AND MEASURES Breast cancer–specific survival assessed by Kaplan-Meier analyses and multivariate Cox proportional hazard modeling, adjusted for treatment, patient age, year of diagnosis, tumor size, grade, hormone receptors, and ERBB2/HER2 and Ki67 status. RESULTS In this secondary analysis of node-negative postmenopausal women, conducted in the era before mammography screening, among the 652 women with MammaPrint scoring available (median age, 62.8 years of age), 377 (58%) and 275 (42%) were MammaPrint low and high risk, respectively, while 98 (15%) were ultralow risk. At 20 years, women with 70-gene high and low tumors but not ultralow tumors had a significantly higher risk of disease-specific death compared with ultralow-risk patients by Cox analysis (hazard ratios, 4.73 [95% CI, 1.38-16.22] and 4.54 [95% CI, 1.40-14.80], respectively). There were no deaths in the ultralow-risk tamoxifen-treated arm at 15 years, and these patients had a 20-year disease-specific survival rate of 97%, whereas for untreated patients the survival rate was 94%. Recursive partitioning identified ultralow risk as the most significant predictor of good outcome. In tumors “not ultralow risk,” tumor size greater than 2 cm was the most predictive of outcome. CONCLUSIONS AND RELEVANCE The ultralow-risk threshold of the 70-gene MammaPrint assay can identify patients whose long-term systemic risk of death from breast cancer after surgery alone is exceedingly low.

UR - http://www.scopus.com/inward/record.url?scp=85028022297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028022297&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2017.1261

DO - 10.1001/jamaoncol.2017.1261

M3 - Article

C2 - 28662222

AN - SCOPUS:85028022297

VL - 3

SP - 1503

EP - 1510

JO - JAMA oncology

JF - JAMA oncology

SN - 2374-2437

IS - 11

ER -